Other glucose-lowering × glycemic control

TrialNature medicine2022

Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial.

Wenying Yang et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 767 people · 2022

Randomised comparison

Probably lowered glycemic control

−0.66percentage points−0.79 to −0.53

As reported

difference −0.66 %, 95% CI −0.79 to −0.53

One number in the abstract

the abstract, start to end

group (estimated treatment difference, -0.66%; 95% CI: -0.79, -0.53;

← favours treatmentfavours comparator →
could be chance
Glycemic control
−0.66−0.79 to −0.53
Other glucose-loweringGlycemic control

Other glucose-lowering × glycemic controlhelps?mixed

unlikelylikely
0.500.50 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

39 papers cite it

2022
2023
2024
2025
2026
this paperpooled ittrialcites it

2 trials

Full record →Abstract, authors, funding and every citing paper · PMID 35551292